title: Safe Treatment of Seizures in the Setting of HIV/AIDS.
abstract: HIV(+) patients are at increased risk for developing seizures due to the vulnerability of the central nervous system to HIV-associated diseases, immune dysfunction, and metabolic disturbances. In patients with acute seizures, standard protocols still apply with urgent seizure cessation being the priority. Management of the person with established epilepsy who contracts HIV is challenging, but the decision to initiate chronic antiepileptic drug (AED) therapy in an HIV(+) patient is also difficult. Chronic treatment guidelines emphasize the interactions between AEDs and antiretroviral (ARV) medications, but provide no explicit advice regarding when to initiate an AED, what medication to select, and/or the duration of treatment. Epidemiologic data regarding seizure recurrence risk in HIV(+) individuals is not available. The risk of further seizures likely depends upon the underlying etiology for the seizure(s) and patients' immune status and may be increased by the use of efavirenz (an ARV). The issues for consideration include AED-ARV interactions, organ dysfunction, seizure type, and drug side effects, which may worsen or be confused with symptoms of HIV and/or epilepsy. Co-administration of enzyme inducing (EI)-AEDs and ARVs can result in virological failure, breakthrough seizure activity, AED toxicity, and/or ARV toxicity. Where available, the AED of choice in HIV(+) patients is levetiracetam due to its broad spectrum activity, ease of use, minimal drug interactions, and favorable side effect profile. Lacosamide, gabapentin, and pregabalin are also favored choices in patients with partial onset seizures and/or those failing levetiracetam. Where newer AEDs are not available, valproic acid may be the treatment of choice in terms of an AED, which will not cause enzyme induction-associated ARV failure, but its side effect profile causes other obvious problems. In resource-limited settings (RLS) where only EI-AEDs are available, there are no good treatment options and further pressure needs to be placed upon policymakers to address this care gap and public health threat.
authors: Beth Israel Deaconess Medical Center, Boston, MA, USA, osiddiqi@bidmc.harvard.edu.
authors: Omar
authors: O
authors: Siddiqi
authors: Gretchen L
authors: GL
authors: Birbeck
references: J Infect Dis. 2012 Nov;206(9):1453-61
references: 22927450
references: Br J Clin Pharmacol. 2006 Feb;61(2):148-54
references: 16433869
references: Antimicrob Agents Chemother. 2004 Nov;48(11):4328-31
references: 15504860
references: AIDS Read. 2008 Jul;18(7):386-8, C3
references: 18655316
references: Lancet Neurol. 2006 Apr;5(4):317-22
references: 16545748
references: Epilepsia. 2007 Mar;48(3):435-41
references: 17319920
references: Epilepsia. 1999;40 Suppl 1:S3-8; discussion S21-2
references: 10421556
references: Neurology. 1994 Jun;44(6 Suppl 5):S17-22; discussion S31-2
references: 8022536
references: Ann Pharmacother. 2004 Mar;38(3):482-9
references: 14970370
references: Epilepsia. 2004;45 Suppl 6:13-8
references: 15315511
references: N Engl J Med. 1992 Mar 5;326(10):668-72
references: 1346547
references: Neurology. 2007 Oct 23;69(17):1715-8
references: 17954787
references: Epilepsia. 2008 Feb;49(2):316-9
references: 17919301
references: JAMA. 1979 Jan 19;241(3):264-8
references: 102806
references: Ann Intern Med. 1990 Jan 1;112(1):35-49
references: 2403474
references: Mycopathologia. 2012 Jun;173(5-6):321-7
references: 22130645
references: J NeuroAIDS. 1996;1(4):59-69
references: 16873179
references: J Gen Virol. 1996 Sep;77 ( Pt 9):1993-9
references: 8810995
references: Epilepsy Behav. 2011 Apr;20(4):725-7
references: 21411374
references: J Clin Pharmacol. 2009 Oct;49(10):1220-7
references: 19717722
references: Epilepsia. 2013 Jan;54(1):66-74
references: 22779776
references: Neurosci Lett. 2011 Jun 27;497(3):223-30
references: 21362451
references: J Acquir Immune Defic Syndr. 2006 Oct 1;43(2):193-6
references: 16940857
references: Clin Pharmacokinet. 1999 Apr;36(4):289-304
references: 10320951
references: Am J Med. 1993 Feb;94(2):169-74
references: 8430712
references: JAMA. 1990 Feb 16;263(7):973-8
references: 2299765
references: J Clin Neurophysiol. 2001 Sep;18(5):419-28
references: 11709647
references: Br J Pharmacol. 2006 Jan;147 Suppl 1:S232-40
references: 16402109
references: Am J Med. 1989 Aug;87(2):173-7
references: 2757058
references: J Neurosurg. 2011 Dec;115(6):1248-55
references: 21838505
references: Neurology. 2000 Apr 11;54(7):1404-7
references: 10751246
references: Br J Clin Pharmacol. 2006 Mar;61(3):246-55
references: 16487217
references: Epilepsia. 2007 Jan;48(1):43-58
references: 17241207
references: Rev Neurol (Paris). 2004 Jun;160 Spec No 1:5S354-67
references: 15331984
references: Seizure. 2011 Jan;20(1):80-2
references: 20952215
references: Clin Ther. 2003 May;25(5):1382-406
references: 12867216
references: Epilepsia. 1999 Jan;40(1):120-2
references: 9924914
references: AIDS Res Ther. 2011 May 16;8:18
references: 21575228
references: Pediatr Infect Dis J. 2011 Nov;30(11):1001-3
references: 21633320
references: Neurol Clin. 1999 Nov;17(4):737-59
references: 10517926
references: Epilepsy Curr. 2009 Jan-Feb;9(1):1-9
references: 19396339
references: Lancet Neurol. 2003 Aug;2(8):473-81
references: 12878435
references: Antivir Ther. 2012;17(3):589-92
references: 22293514
references: Acta Neurol Belg. 1999 Dec;99(4):275-80
references: 10674145
references: Ann Pharmacother. 1999 Apr;33(4):461-73
references: 10332538
references: Clin Pharmacokinet. 1997 Mar;32(3):194-209
references: 9084959
references: Neurology. 2012 Jan 10;78(2):139-45
references: 22218281
references: Neurology. 2006 Jan 24;66(2):262-4
references: 16434670
references: AIDS. 2008 Jun 19;22(10):1125-9
references: 18525257
references: Epilepsia. 1999;40 Suppl 8:32-9
references: 10563593
references: Eur J Clin Pharmacol. 2008 Apr;64(4):357-65
references: 18057928
references: Epilepsia. 2009 Dec;50 Suppl 12:64-6
references: 19941530
references: Clin Pharmacol Ther. 2006 Aug;80(2):159-68
references: 16890577
references: Neurology. 2003 Nov 11;61(9):1218-21
references: 14610123
references: Ann Pharmacother. 1999 Oct;33(10):1113-6
references: 10534224
references: Epilepsia. 2008;49 Suppl 1:13-8
references: 18184149
references: Seizure. 2008 Jan;17(1):27-33
references: 17618132
references: J Clin Pharmacol. 2008 Aug;48(8):948-56
references: 18519918
references: Arch Neurol. 1990 Jun;47(6):640-2
references: 2346390
references: Tuberc Res Treat. 2011;2011:798764
references: 22567269
references: AIDS Res Hum Retroviruses. 1997 Jan 20;13(2):187-92
references: 9007204
references: J Pharmacol Exp Ther. 2003 Jul;306(1):287-300
references: 12676886
references: Infection. 2003 Dec;31(6):387-91
references: 14735380
references: Clin Pharmacol Ther. 1994 Sep;56(3):272-8
references: 7924122
references: Lancet Neurol. 2003 Jun;2(6):347-56
references: 12849151
references: Epilepsy Res. 2011 Mar;94(1-2):61-8
references: 21306874
references: Ther Adv Neurol Disord. 2010 Mar;3(2):85-92
references: 21179601
references: Ther Drug Monit. 2002 Feb;24(1):91-103
references: 11805729
references: J Neuropathol Exp Neurol. 2005 Jun;64(6):529-36
references: 15977645
references: Lancet Neurol. 2012 Oct;11(10):878-90
references: 22995692
references: Epilepsia. 2011 Oct;52(10):e153-5
references: 21801173
references: Neurology. 1991 Jul;41(7):965-72
references: 2067659